Abstract

Existing preclinical methods for acquiring dissemination kinetics of rare circulating tumor cells (CTCs) en route to forming metastases have not been capable of providing a direct measure of CTC intravasation rate and subsequent half-life in the circulation. Here, we demonstrate an approach for measuring endogenous CTC kinetics by continuously exchanging CTC-containing blood over several hours between un-anesthetized, tumor-bearing mice and healthy, tumor-free counterparts. By tracking CTC transfer rates, we extrapolated half-life times in the circulation of between 40 and 260 s and intravasation rates between 60 and 107,000 CTCs/hour in mouse models of small-cell lung cancer (SCLC), pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC). Additionally, direct transfer of only 1−2% of daily-shed CTCs using our blood-exchange technique from late-stage, SCLC-bearing mice generated macrometastases in healthy recipient mice. We envision that our technique will help further elucidate the role of CTCs and the rate-limiting steps in metastasis.

Current methods for acquiring dissemination kinetics of rare circulating tumor cells (CTCs) that form metastases have several limitations. Here, the authors show an approach for measuring endogenous CTC kinetics by continuously exchanging CTC-containing blood between un-anesthetized, tumor-bearing mice and healthy, tumor-free counterparts.

Details

Title
Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice
Author
Hamza Bashar 1 ; Miller, Alex B 2   VIAFID ORCID Logo  ; Meier, Lara 3 ; Stockslager Max 4 ; Ng, Sheng Rong 5   VIAFID ORCID Logo  ; King, Emily M 6 ; Lin, Lin 6 ; DeGouveia, Kelsey L 7 ; Nolawit, Mulugeta 6 ; Calistri, Nicholas L 6   VIAFID ORCID Logo  ; Haley, Strouf 6 ; Bray, Christina 6 ; Rodriguez, Felicia 8 ; Freed-Pastor, William A 9 ; Chin, Christopher R 6   VIAFID ORCID Logo  ; Jaramillo, Grissel C 5 ; Burger, Megan L 6 ; Weinberg, Robert A 10   VIAFID ORCID Logo  ; Shalek, Alex K 11   VIAFID ORCID Logo  ; Jacks Tyler 5   VIAFID ORCID Logo  ; Manalis, Scott R 12   VIAFID ORCID Logo 

 Massachusetts Institute of Technology, Department of Electrical Engineering and Computer Science, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Massachusetts Institute of Technology, David H. Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 Massachusetts Institute of Technology, David H. Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Harvard-MIT Department of Health Sciences and Technology, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 Massachusetts Institute of Technology, David H. Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); University Medical Center Hamburg-Eppendorf, Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Comprehensive Cancer Center Hamburg, Hamburg, Germany (GRID:grid.13648.38) (ISNI:0000 0001 2180 3484); University Medical Center Hamburg-Eppendorf, Department of Tumor Biology, Center of Experimental Medicine, Hamburg, Germany (GRID:grid.13648.38) (ISNI:0000 0001 2180 3484) 
 Massachusetts Institute of Technology, David H. Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Massachusetts Institute of Technology, Department of Mechanical Engineering, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 Massachusetts Institute of Technology, David H. Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Massachusetts Institute of Technology, Department of Biology, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 Massachusetts Institute of Technology, David H. Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 Massachusetts Institute of Technology, David H. Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Wentworth Institute of Technology, Department of Biomedical Engineering, Boston, USA (GRID:grid.422596.e) (ISNI:0000 0001 0639 028X) 
 Massachusetts Institute of Technology, David H. Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Massachusetts Institute of Technology, Department of Biological Engineering, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
 Massachusetts Institute of Technology, David H. Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
10  Massachusetts Institute of Technology, David H. Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Massachusetts Institute of Technology, Department of Biology, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Whitehead Institute for Biomedical Research, Cambridge, USA (GRID:grid.270301.7) (ISNI:0000 0001 2292 6283) 
11  Massachusetts Institute of Technology, David H. Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Harvard-MIT Department of Health Sciences and Technology, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Massachusetts Institute of Technology, Department of Chemistry, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Massachusetts Institute of Technology, Institute for Medical Engineering and Science, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34); MIT and Harvard University, Ragon Institute of MGH, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Massachusetts General Hospital, Department of Immunology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
12  Massachusetts Institute of Technology, David H. Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Massachusetts Institute of Technology, Department of Mechanical Engineering, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Massachusetts Institute of Technology, Department of Biological Engineering, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786); Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34); Ludwig Center at MIT’s Koch Institute for Integrative Cancer Research, Cambridge, USA (GRID:grid.116068.8) (ISNI:0000 0001 2341 2786) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2576852578
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.